SE0102147D0 - New methods - Google Patents

New methods

Info

Publication number
SE0102147D0
SE0102147D0 SE0102147A SE0102147A SE0102147D0 SE 0102147 D0 SE0102147 D0 SE 0102147D0 SE 0102147 A SE0102147 A SE 0102147A SE 0102147 A SE0102147 A SE 0102147A SE 0102147 D0 SE0102147 D0 SE 0102147D0
Authority
SE
Sweden
Prior art keywords
methods
mnk2b
mnk2a
relates
new methods
Prior art date
Application number
SE0102147A
Other languages
English (en)
Swedish (sv)
Inventor
Christina Bendz
Staffan Lake
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20284509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0102147(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE0102147A priority Critical patent/SE0102147D0/xx
Publication of SE0102147D0 publication Critical patent/SE0102147D0/xx
Priority to PCT/SE2002/001268 priority patent/WO2002103361A1/en
Priority to AT02739056T priority patent/ATE356995T1/de
Priority to EP02739056A priority patent/EP1397681B1/en
Priority to PT02739056T priority patent/PT1397681E/pt
Priority to CA002446284A priority patent/CA2446284A1/en
Priority to JP2003505626A priority patent/JP4475945B2/ja
Priority to DE60218843T priority patent/DE60218843T2/de
Priority to US10/174,784 priority patent/US20030022241A1/en
Priority to ES02739056T priority patent/ES2284879T3/es
Priority to AU2002311737A priority patent/AU2002311737B2/en
Priority to DK02739056T priority patent/DK1397681T3/da
Priority to CY20071100708T priority patent/CY1107640T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SE0102147A 2001-06-18 2001-06-18 New methods SE0102147D0 (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE0102147A SE0102147D0 (sv) 2001-06-18 2001-06-18 New methods
DK02739056T DK1397681T3 (da) 2001-06-18 2002-06-18 Fremgangsmåde til identificering af midler til behandling af diabetes
AU2002311737A AU2002311737B2 (en) 2001-06-18 2002-06-18 Method for identification of agents for the treatment of diabetes
CA002446284A CA2446284A1 (en) 2001-06-18 2002-06-18 Method for identification of agents for the treatment of diabetes
AT02739056T ATE356995T1 (de) 2001-06-18 2002-06-18 Verfahren zur identifizierung von mitteln zur behandlung von diabetes
EP02739056A EP1397681B1 (en) 2001-06-18 2002-06-18 Method for identification of agents for the treatment of diabetes
PT02739056T PT1397681E (pt) 2001-06-18 2002-06-18 Processos para a identificação de agentes para o tratamento de diabetes
PCT/SE2002/001268 WO2002103361A1 (en) 2001-06-18 2002-06-18 Method for identification of agents for the treatment of diabetes
JP2003505626A JP4475945B2 (ja) 2001-06-18 2002-06-18 糖尿病処置のための作用物質同定法
DE60218843T DE60218843T2 (de) 2001-06-18 2002-06-18 Verfahren zur identifizierung von mitteln zur behandlung von diabetes
US10/174,784 US20030022241A1 (en) 2001-06-18 2002-06-18 Methods
ES02739056T ES2284879T3 (es) 2001-06-18 2002-06-18 Metodo para la identificacion de agentes para el tratamiento de la diabetes.
CY20071100708T CY1107640T1 (el) 2001-06-18 2007-05-25 Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102147A SE0102147D0 (sv) 2001-06-18 2001-06-18 New methods

Publications (1)

Publication Number Publication Date
SE0102147D0 true SE0102147D0 (sv) 2001-06-18

Family

ID=20284509

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0102147A SE0102147D0 (sv) 2001-06-18 2001-06-18 New methods

Country Status (13)

Country Link
US (1) US20030022241A1 (xx)
EP (1) EP1397681B1 (xx)
JP (1) JP4475945B2 (xx)
AT (1) ATE356995T1 (xx)
AU (1) AU2002311737B2 (xx)
CA (1) CA2446284A1 (xx)
CY (1) CY1107640T1 (xx)
DE (1) DE60218843T2 (xx)
DK (1) DK1397681T3 (xx)
ES (1) ES2284879T3 (xx)
PT (1) PT1397681E (xx)
SE (1) SE0102147D0 (xx)
WO (1) WO2002103361A1 (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500813A (ja) * 2001-01-12 2005-01-13 エクセリクシス・インコーポレイテッド インスリン受容体シグナル伝達の調節
US20050080026A1 (en) 2001-10-29 2005-04-14 Arnd Steuernagel Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism
US20050202407A1 (en) * 2003-12-01 2005-09-15 Baylor College Of Medicine Methods and assays for screening anti-neoplastic therapeutic agents
US7790693B2 (en) * 2004-12-02 2010-09-07 University Of Massachusetts Glucose-transport related genes, polypeptides, and methods of use thereof
ZA200807715B (en) 2006-03-09 2009-11-25 Pharmacopeia Inc 9-Heteroarylpurine MNK2 inhibitors for treating metabolic disorders
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
WO2011104338A1 (en) 2010-02-26 2011-09-01 Boehringer Ingelheim International Gmbh Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
EP2539345B1 (en) 2010-02-26 2015-07-22 Boehringer Ingelheim International GmbH 4-[cycloalkyloxy(hetero)arylamino]-thieno[2,3-d]pyrimidines having mnk1/ mnk2 inhibiting activity for pharmaceutical compositions
CA2791114A1 (en) 2010-02-26 2011-09-01 Boehringer Ingelheim International Gmbh Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
WO2014072244A1 (en) 2012-11-09 2014-05-15 Boehringer Ingelheim International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
CA2929742C (en) 2013-12-04 2022-09-20 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
WO2015091156A1 (en) 2013-12-17 2015-06-25 Boehringer Ingelheim International Gmbh Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions
JP6479854B2 (ja) 2014-05-07 2019-03-06 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＥｖｏｔｅｃ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 医薬組成物のためのスルホキシイミン置換キナゾリン
EP3365337A1 (en) 2015-10-22 2018-08-29 Selvita S.A. Pyridone derivatives and their use as kinase inhibitors
WO2017165908A1 (en) * 2016-03-31 2017-10-05 South Australian Health And Medical Research Institute Limited Method of inhibiting high fat diet-related conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874231A (en) * 1994-08-22 1999-02-23 Mcgill University Methods of screening for non-hormone compounds which effect modulation of polypeptide translation
US6057117A (en) * 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3

Also Published As

Publication number Publication date
JP4475945B2 (ja) 2010-06-09
DE60218843D1 (de) 2007-04-26
EP1397681B1 (en) 2007-03-14
EP1397681A1 (en) 2004-03-17
ES2284879T3 (es) 2007-11-16
US20030022241A1 (en) 2003-01-30
CA2446284A1 (en) 2002-12-27
PT1397681E (pt) 2007-06-19
DE60218843T2 (de) 2007-07-12
AU2002311737B2 (en) 2007-06-21
JP2005500033A (ja) 2005-01-06
CY1107640T1 (el) 2013-04-18
WO2002103361A1 (en) 2002-12-27
ATE356995T1 (de) 2007-04-15
DK1397681T3 (da) 2007-07-16

Similar Documents

Publication Publication Date Title
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
ATE408601T1 (de) Fredericamycin-derivate
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
DE60115498D1 (de) Chirurgische vorrichtungen
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
ATE342719T1 (de) Iontophoretische verabreichung von rotigotin zur behandlung der parkinson'schen krankheit
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
ATE552031T1 (de) Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
FR2856294B1 (fr) Utilisation cosmetique d'une composition comprenant au moins une oxazoline, a titre de principe actif, comme amincissant et/ou pour prevenir et/ou traiter la cellulite
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
WO2003062273A3 (en) Modulator of the notch signalling pathway and use thereof in medical treatment
DE69814394D1 (de) Verwendung von levobupivacain
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DE60138189D1 (de) Eine neue verwendung von deferiprone
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
BR0309878A (pt) Heterotriciclil-6-alquilideno-penemas como inibidores de beta-lactamase
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
EA200401454A1 (ru) Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
TR199901385T2 (xx) Piperidin t�revleri.
DE50210279D1 (de) Screeningverfahren mit bnpi und dnpi
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
ATE337783T1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen